Beigene Ltd
HKEX:6160
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
77
150.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Beigene Ltd
Beigene Ltd
Cost of Revenue
Beigene Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beigene Ltd
HKEX:6160
|
Cost of Revenue
-¥2.7B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Cost of Revenue
-¥137.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cost of Revenue
-¥992.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cost of Revenue
-¥5B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-33%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cost of Revenue
-¥35.1B
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-62%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cost of Revenue
-¥140.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
Glance View
Beigene Ltd. has emerged as a formidable player in the global biopharmaceutical landscape, primarily focusing on the discovery and development of innovative medicines to treat cancer. Founded in 2010, the company has quickly established itself with a strong commitment to addressing the significant unmet medical needs in oncology. Headquartered in Beijing, China, Beigene's expansive R&D efforts are complemented by an extensive portfolio of targeted therapies, including BTK inhibitors and PD-1 antibodies, which have garnered attention for their effectiveness in treating various malignancies. What sets Beigene apart is its strategic emphasis on global collaboration, combining scientific expertise with a patient-centric approach to accelerate the development of breakthrough therapies. Investors find Beigene's aggressive growth strategy particularly appealing, as the company not only pursues internal drug development but also engages in partnerships and collaborations to enhance its pipeline and market reach. Recently, Beigene's acquisition of the global rights to several key therapies has bolstered its position in the U.S. market, giving it the resources necessary to compete on a larger scale. With its dual listing on both the Nasdaq and the Hong Kong Stock Exchange, Beigene showcases its ambition and adaptability in a rapidly evolving sector. As the company continues to innovate and expand its footprint, it stands poised to capitalize on the increasing global demand for cancer treatments, making it an intriguing prospect for long-term investors seeking exposure to the dynamic biotech industry.
See Also
What is Beigene Ltd's Cost of Revenue?
Cost of Revenue
-2.7B
CNY
Based on the financial report for Dec 31, 2023, Beigene Ltd's Cost of Revenue amounts to -2.7B CNY.
What is Beigene Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-70%
Over the last year, the Cost of Revenue growth was -42%. The average annual Cost of Revenue growth rates for Beigene Ltd have been -77% over the past three years , -70% over the past five years .
You don't have any saved screeners yet
